Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis.

GastroenterologyApr 1, 2026 (epub)
Clinical ResearchGastroenterology

Daryl Ramai, Chun-Wei Pan, Bjorn Rodriguez et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and network meta-analysis compared eight strategies for increasing colorectal cancer screening uptake across 76 randomized clinical trials. Patient navigation and mailed fecal immunochemical test (FIT) outreach significantly outperformed usual care: navigation had an RR of 1.58 (95% CI, 1.23-2.02), and mailed FIT outreach an RR of 1.36 (95% CI, 1.07-1.74). Mailed FIT outreach was particularly effective where baseline uptake was below 30%. Evidence certainty was mostly moderate to low, and educational multimedia showed promise in higher-uptake settings and recent studies.

Key findings

  • Patient navigation increased screening uptake versus usual care (RR, 1.58; 95% CI, 1.23-2.02).
  • Mailed FIT outreach increased uptake versus usual care (RR, 1.36; 95% CI, 1.07-1.74) and outperformed colonoscopy outreach (RR, 1.35; 95% CI, 1.11-1.63).
  • In settings with baseline uptake below 30%, mailed FIT outreach had an RR of 3.12 (95% CI, 1.70-5.71).
  • Choice-based and colonoscopy outreach were not significantly more effective than usual care; evidence certainty was mostly moderate to low.

Why it matters

Screening uptake remains suboptimal despite its role in reducing colorectal cancer mortality. These comparative findings suggest that navigation and mailed FIT outreach can improve participation, while the relative performance of strategies may depend on baseline uptake. The review also highlights uncertainty in the evidence, which matters when interpreting rankings and considering how broadly results apply.

What to keep in mind

The certainty of evidence was mostly moderate to low, limiting confidence in comparative rankings. The abstract does not report participant totals or follow-up duration.

Source

Published in Gastroenterology. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.